Loading…

Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma

BACKGROUND Intestinal and diffuse adenocarcinomas of the stomach differ in phenotypic properties, morphology, and growth behavior. Apoptosis (programmed cell death) is induced via specific cell‐surface receptors (SC‐1, Fas/APO‐1/CD95) and coregulated by intracellular molecules (bcl‐2, p53, etc.); th...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1997-02, Vol.79 (3), p.433-440
Main Authors: Vollmers, H. Peter, Dämmrich, Jobst, Hensel, Frank, Ribbert, Hanno, Meyer‐Bahlburg, Almut, Ufken‐Gaul, Tobias, Korff, Marlene v., Müller‐Hermelink, Hans Konrad
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c4752-3425639efd469e8dc59277262cc498ac8f4aa8bde348b7c0b2ee1a28fcffeab23
container_end_page 440
container_issue 3
container_start_page 433
container_title Cancer
container_volume 79
creator Vollmers, H. Peter
Dämmrich, Jobst
Hensel, Frank
Ribbert, Hanno
Meyer‐Bahlburg, Almut
Ufken‐Gaul, Tobias
Korff, Marlene v.
Müller‐Hermelink, Hans Konrad
description BACKGROUND Intestinal and diffuse adenocarcinomas of the stomach differ in phenotypic properties, morphology, and growth behavior. Apoptosis (programmed cell death) is induced via specific cell‐surface receptors (SC‐1, Fas/APO‐1/CD95) and coregulated by intracellular molecules (bcl‐2, p53, etc.); the success of apoptotic processes is dependent on the expression of these signals. Differences in the expression of specific apoptosis receptors and intracellular‐related signals might help to explain the molecular pathogenesis of these two types of stomach adenocarcinoma. METHODS Immunohistochemical studies were performed on frozen sections of tumor tissue using human monoclonal antibody SC‐1 and murine monoclonal antibodies Fas and p53, followed by peroxidase‐coupled second antibodies. To determine binding of SC‐1 and Fas antibodies to stomach carcinoma cells on the molecular level, Western blot analysis was performed with cell extract preparations from stomach carcinoma cells. To investigate functional apoptotic activity, MTT assays were performed with SC‐1 and Fas antibodies on stomach carcinoma cells. RESULTS On frozen sections intestinal type stomach carcinoma cells demonstrate little or no expression of SC‐1 and Fas receptors (4 of 17 and 1 of 17, respectively). Diffuse type stomach carcinoma cells show just the opposite: greater than 50% express SC‐1 and Fas at a high level (15 of 30 and 22 of 30, respectively). Normal stomach mucosa is negative with both antibodies. Expression of p53 is positively correlated with intestinal type carcinomas (11 of 17) but not with diffuse type (5 of 30). In functional studies (MTT assay) the SC‐1 and Fas antibodies react with stomach carcinoma by inducing apoptosis and inhibiting growth. On Western blot analysis of extracts from stomach carcinoma cells, SC‐1 detects a protein of 50 kilodalton (kD) and Fas proteins of approximately 30, 45, and 60 kD. CONCLUSIONS These data indicate that gastric carcinoma cells of the intestinal and diffuse type differ in their expression of the apoptotic receptors SC‐1 and Fas and the tumor suppressor gene product p53. These new data on phenotypic differences support the hypothesis that these two types of stomach carcinoma do not only differ in morphology, growth pattern, and risk factors but also in genetic pathways. Cancer 1997; 79:433‐40. © 1997 American Cancer Society. Adenocarcinomas of the stomach can be divided into intestinal and diffuse types. They differ in their morphology and g
doi_str_mv 10.1002/(SICI)1097-0142(19970201)79:3<433::AID-CNCR2>3.0.CO;2-J
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78819760</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78819760</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4752-3425639efd469e8dc59277262cc498ac8f4aa8bde348b7c0b2ee1a28fcffeab23</originalsourceid><addsrcrecordid>eNqFkN1v0zAUxS3ENLrBn4CUB4S2hxR_pbYL2jRlDDpNVOJD7O3KcW6EUZpkdirof49LS19A4snX95x7dPQj5JLRKaOUvzr7tCgX54walVMm-RkzRlFO2bkyc_FGCjGfXy2u8_JD-ZFfiCmdlsvXPL99RCaHm8dkQinVeSHF_RNyEuP39FW8EMfk2FCuRcEmBK5902DAbvS2zfDnEDBG33dZ32R26Iexjz5mAR2mMcQsKXW6WEfMbFdnvhsxjr5Lt-NmwCyO_cq6b5mzwfkuzU_JUWPbiM_27yn5cvP2c_k-v1u-W5RXd7mTquC5kLyYCYNNLWcGde0Kw5XiM-6cNNo63UhrdVWjkLpSjlYckVmuG5fa24qLU_JylzuE_mGdOsHKR4dtazvs1xGU1syoGU3GrzujC32MARsYgl_ZsAFGYYseYIsethhhixH-oAdlQEBCD5DQw2_0aUGhXAKH25T8fF9hXa2wPuTuWSf9xV630dm2CbZzPh5svJBUKZFs9zvbD9_i5q92_y33r267hfgF2Miufw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78819760</pqid></control><display><type>article</type><title>Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><source>Elektronische Zeitschriftenbibliothek</source><creator>Vollmers, H. Peter ; Dämmrich, Jobst ; Hensel, Frank ; Ribbert, Hanno ; Meyer‐Bahlburg, Almut ; Ufken‐Gaul, Tobias ; Korff, Marlene v. ; Müller‐Hermelink, Hans Konrad</creator><creatorcontrib>Vollmers, H. Peter ; Dämmrich, Jobst ; Hensel, Frank ; Ribbert, Hanno ; Meyer‐Bahlburg, Almut ; Ufken‐Gaul, Tobias ; Korff, Marlene v. ; Müller‐Hermelink, Hans Konrad</creatorcontrib><description>BACKGROUND Intestinal and diffuse adenocarcinomas of the stomach differ in phenotypic properties, morphology, and growth behavior. Apoptosis (programmed cell death) is induced via specific cell‐surface receptors (SC‐1, Fas/APO‐1/CD95) and coregulated by intracellular molecules (bcl‐2, p53, etc.); the success of apoptotic processes is dependent on the expression of these signals. Differences in the expression of specific apoptosis receptors and intracellular‐related signals might help to explain the molecular pathogenesis of these two types of stomach adenocarcinoma. METHODS Immunohistochemical studies were performed on frozen sections of tumor tissue using human monoclonal antibody SC‐1 and murine monoclonal antibodies Fas and p53, followed by peroxidase‐coupled second antibodies. To determine binding of SC‐1 and Fas antibodies to stomach carcinoma cells on the molecular level, Western blot analysis was performed with cell extract preparations from stomach carcinoma cells. To investigate functional apoptotic activity, MTT assays were performed with SC‐1 and Fas antibodies on stomach carcinoma cells. RESULTS On frozen sections intestinal type stomach carcinoma cells demonstrate little or no expression of SC‐1 and Fas receptors (4 of 17 and 1 of 17, respectively). Diffuse type stomach carcinoma cells show just the opposite: greater than 50% express SC‐1 and Fas at a high level (15 of 30 and 22 of 30, respectively). Normal stomach mucosa is negative with both antibodies. Expression of p53 is positively correlated with intestinal type carcinomas (11 of 17) but not with diffuse type (5 of 30). In functional studies (MTT assay) the SC‐1 and Fas antibodies react with stomach carcinoma by inducing apoptosis and inhibiting growth. On Western blot analysis of extracts from stomach carcinoma cells, SC‐1 detects a protein of 50 kilodalton (kD) and Fas proteins of approximately 30, 45, and 60 kD. CONCLUSIONS These data indicate that gastric carcinoma cells of the intestinal and diffuse type differ in their expression of the apoptotic receptors SC‐1 and Fas and the tumor suppressor gene product p53. These new data on phenotypic differences support the hypothesis that these two types of stomach carcinoma do not only differ in morphology, growth pattern, and risk factors but also in genetic pathways. Cancer 1997; 79:433‐40. © 1997 American Cancer Society. Adenocarcinomas of the stomach can be divided into intestinal and diffuse types. They differ in their morphology and growth behavior and in addition, as shown in this study, in their expression of the apoptosis‐related cell‐surface receptors SC‐1 and Fas and the tumor suppressor gene product p53.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/(SICI)1097-0142(19970201)79:3&lt;433::AID-CNCR2&gt;3.0.CO;2-J</identifier><identifier>PMID: 9028351</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: John Wiley &amp; Sons, Inc</publisher><subject>Adenocarcinoma - chemistry ; Adenocarcinoma - immunology ; Adenocarcinoma - physiopathology ; Adult ; Aged ; apoptosis ; Apoptosis - physiology ; Biological and medical sciences ; Blotting, Western ; Coloring Agents ; diffuse type stomach carcinoma ; Electrophoresis ; fas Receptor - analysis ; Fas/APO‐1/CD95 ; Female ; Frozen Sections ; Gastroenterology. Liver. Pancreas. Abdomen ; Gene Expression Regulation, Neoplastic ; Humans ; Immunoenzyme Techniques ; intestinal type stomach carcinoma ; Male ; Medical sciences ; Middle Aged ; p53 ; Receptors, Cell Surface - analysis ; SC‐1 ; Stomach ; Stomach Neoplasms - chemistry ; Stomach Neoplasms - immunology ; Stomach Neoplasms - physiopathology ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Tetrazolium Salts ; Thiazoles ; Tumor Suppressor Protein p53 - analysis ; Tumors</subject><ispartof>Cancer, 1997-02, Vol.79 (3), p.433-440</ispartof><rights>Copyright © 1997 American Cancer Society</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4752-3425639efd469e8dc59277262cc498ac8f4aa8bde348b7c0b2ee1a28fcffeab23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2540773$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9028351$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vollmers, H. Peter</creatorcontrib><creatorcontrib>Dämmrich, Jobst</creatorcontrib><creatorcontrib>Hensel, Frank</creatorcontrib><creatorcontrib>Ribbert, Hanno</creatorcontrib><creatorcontrib>Meyer‐Bahlburg, Almut</creatorcontrib><creatorcontrib>Ufken‐Gaul, Tobias</creatorcontrib><creatorcontrib>Korff, Marlene v.</creatorcontrib><creatorcontrib>Müller‐Hermelink, Hans Konrad</creatorcontrib><title>Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND Intestinal and diffuse adenocarcinomas of the stomach differ in phenotypic properties, morphology, and growth behavior. Apoptosis (programmed cell death) is induced via specific cell‐surface receptors (SC‐1, Fas/APO‐1/CD95) and coregulated by intracellular molecules (bcl‐2, p53, etc.); the success of apoptotic processes is dependent on the expression of these signals. Differences in the expression of specific apoptosis receptors and intracellular‐related signals might help to explain the molecular pathogenesis of these two types of stomach adenocarcinoma. METHODS Immunohistochemical studies were performed on frozen sections of tumor tissue using human monoclonal antibody SC‐1 and murine monoclonal antibodies Fas and p53, followed by peroxidase‐coupled second antibodies. To determine binding of SC‐1 and Fas antibodies to stomach carcinoma cells on the molecular level, Western blot analysis was performed with cell extract preparations from stomach carcinoma cells. To investigate functional apoptotic activity, MTT assays were performed with SC‐1 and Fas antibodies on stomach carcinoma cells. RESULTS On frozen sections intestinal type stomach carcinoma cells demonstrate little or no expression of SC‐1 and Fas receptors (4 of 17 and 1 of 17, respectively). Diffuse type stomach carcinoma cells show just the opposite: greater than 50% express SC‐1 and Fas at a high level (15 of 30 and 22 of 30, respectively). Normal stomach mucosa is negative with both antibodies. Expression of p53 is positively correlated with intestinal type carcinomas (11 of 17) but not with diffuse type (5 of 30). In functional studies (MTT assay) the SC‐1 and Fas antibodies react with stomach carcinoma by inducing apoptosis and inhibiting growth. On Western blot analysis of extracts from stomach carcinoma cells, SC‐1 detects a protein of 50 kilodalton (kD) and Fas proteins of approximately 30, 45, and 60 kD. CONCLUSIONS These data indicate that gastric carcinoma cells of the intestinal and diffuse type differ in their expression of the apoptotic receptors SC‐1 and Fas and the tumor suppressor gene product p53. These new data on phenotypic differences support the hypothesis that these two types of stomach carcinoma do not only differ in morphology, growth pattern, and risk factors but also in genetic pathways. Cancer 1997; 79:433‐40. © 1997 American Cancer Society. Adenocarcinomas of the stomach can be divided into intestinal and diffuse types. They differ in their morphology and growth behavior and in addition, as shown in this study, in their expression of the apoptosis‐related cell‐surface receptors SC‐1 and Fas and the tumor suppressor gene product p53.</description><subject>Adenocarcinoma - chemistry</subject><subject>Adenocarcinoma - immunology</subject><subject>Adenocarcinoma - physiopathology</subject><subject>Adult</subject><subject>Aged</subject><subject>apoptosis</subject><subject>Apoptosis - physiology</subject><subject>Biological and medical sciences</subject><subject>Blotting, Western</subject><subject>Coloring Agents</subject><subject>diffuse type stomach carcinoma</subject><subject>Electrophoresis</subject><subject>fas Receptor - analysis</subject><subject>Fas/APO‐1/CD95</subject><subject>Female</subject><subject>Frozen Sections</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>intestinal type stomach carcinoma</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>p53</subject><subject>Receptors, Cell Surface - analysis</subject><subject>SC‐1</subject><subject>Stomach</subject><subject>Stomach Neoplasms - chemistry</subject><subject>Stomach Neoplasms - immunology</subject><subject>Stomach Neoplasms - physiopathology</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Tetrazolium Salts</subject><subject>Thiazoles</subject><subject>Tumor Suppressor Protein p53 - analysis</subject><subject>Tumors</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNqFkN1v0zAUxS3ENLrBn4CUB4S2hxR_pbYL2jRlDDpNVOJD7O3KcW6EUZpkdirof49LS19A4snX95x7dPQj5JLRKaOUvzr7tCgX54walVMm-RkzRlFO2bkyc_FGCjGfXy2u8_JD-ZFfiCmdlsvXPL99RCaHm8dkQinVeSHF_RNyEuP39FW8EMfk2FCuRcEmBK5902DAbvS2zfDnEDBG33dZ32R26Iexjz5mAR2mMcQsKXW6WEfMbFdnvhsxjr5Lt-NmwCyO_cq6b5mzwfkuzU_JUWPbiM_27yn5cvP2c_k-v1u-W5RXd7mTquC5kLyYCYNNLWcGde0Kw5XiM-6cNNo63UhrdVWjkLpSjlYckVmuG5fa24qLU_JylzuE_mGdOsHKR4dtazvs1xGU1syoGU3GrzujC32MARsYgl_ZsAFGYYseYIsethhhixH-oAdlQEBCD5DQw2_0aUGhXAKH25T8fF9hXa2wPuTuWSf9xV630dm2CbZzPh5svJBUKZFs9zvbD9_i5q92_y33r267hfgF2Miufw</recordid><startdate>19970201</startdate><enddate>19970201</enddate><creator>Vollmers, H. Peter</creator><creator>Dämmrich, Jobst</creator><creator>Hensel, Frank</creator><creator>Ribbert, Hanno</creator><creator>Meyer‐Bahlburg, Almut</creator><creator>Ufken‐Gaul, Tobias</creator><creator>Korff, Marlene v.</creator><creator>Müller‐Hermelink, Hans Konrad</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19970201</creationdate><title>Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma</title><author>Vollmers, H. Peter ; Dämmrich, Jobst ; Hensel, Frank ; Ribbert, Hanno ; Meyer‐Bahlburg, Almut ; Ufken‐Gaul, Tobias ; Korff, Marlene v. ; Müller‐Hermelink, Hans Konrad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4752-3425639efd469e8dc59277262cc498ac8f4aa8bde348b7c0b2ee1a28fcffeab23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adenocarcinoma - chemistry</topic><topic>Adenocarcinoma - immunology</topic><topic>Adenocarcinoma - physiopathology</topic><topic>Adult</topic><topic>Aged</topic><topic>apoptosis</topic><topic>Apoptosis - physiology</topic><topic>Biological and medical sciences</topic><topic>Blotting, Western</topic><topic>Coloring Agents</topic><topic>diffuse type stomach carcinoma</topic><topic>Electrophoresis</topic><topic>fas Receptor - analysis</topic><topic>Fas/APO‐1/CD95</topic><topic>Female</topic><topic>Frozen Sections</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>intestinal type stomach carcinoma</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>p53</topic><topic>Receptors, Cell Surface - analysis</topic><topic>SC‐1</topic><topic>Stomach</topic><topic>Stomach Neoplasms - chemistry</topic><topic>Stomach Neoplasms - immunology</topic><topic>Stomach Neoplasms - physiopathology</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Tetrazolium Salts</topic><topic>Thiazoles</topic><topic>Tumor Suppressor Protein p53 - analysis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vollmers, H. Peter</creatorcontrib><creatorcontrib>Dämmrich, Jobst</creatorcontrib><creatorcontrib>Hensel, Frank</creatorcontrib><creatorcontrib>Ribbert, Hanno</creatorcontrib><creatorcontrib>Meyer‐Bahlburg, Almut</creatorcontrib><creatorcontrib>Ufken‐Gaul, Tobias</creatorcontrib><creatorcontrib>Korff, Marlene v.</creatorcontrib><creatorcontrib>Müller‐Hermelink, Hans Konrad</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vollmers, H. Peter</au><au>Dämmrich, Jobst</au><au>Hensel, Frank</au><au>Ribbert, Hanno</au><au>Meyer‐Bahlburg, Almut</au><au>Ufken‐Gaul, Tobias</au><au>Korff, Marlene v.</au><au>Müller‐Hermelink, Hans Konrad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1997-02-01</date><risdate>1997</risdate><volume>79</volume><issue>3</issue><spage>433</spage><epage>440</epage><pages>433-440</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND Intestinal and diffuse adenocarcinomas of the stomach differ in phenotypic properties, morphology, and growth behavior. Apoptosis (programmed cell death) is induced via specific cell‐surface receptors (SC‐1, Fas/APO‐1/CD95) and coregulated by intracellular molecules (bcl‐2, p53, etc.); the success of apoptotic processes is dependent on the expression of these signals. Differences in the expression of specific apoptosis receptors and intracellular‐related signals might help to explain the molecular pathogenesis of these two types of stomach adenocarcinoma. METHODS Immunohistochemical studies were performed on frozen sections of tumor tissue using human monoclonal antibody SC‐1 and murine monoclonal antibodies Fas and p53, followed by peroxidase‐coupled second antibodies. To determine binding of SC‐1 and Fas antibodies to stomach carcinoma cells on the molecular level, Western blot analysis was performed with cell extract preparations from stomach carcinoma cells. To investigate functional apoptotic activity, MTT assays were performed with SC‐1 and Fas antibodies on stomach carcinoma cells. RESULTS On frozen sections intestinal type stomach carcinoma cells demonstrate little or no expression of SC‐1 and Fas receptors (4 of 17 and 1 of 17, respectively). Diffuse type stomach carcinoma cells show just the opposite: greater than 50% express SC‐1 and Fas at a high level (15 of 30 and 22 of 30, respectively). Normal stomach mucosa is negative with both antibodies. Expression of p53 is positively correlated with intestinal type carcinomas (11 of 17) but not with diffuse type (5 of 30). In functional studies (MTT assay) the SC‐1 and Fas antibodies react with stomach carcinoma by inducing apoptosis and inhibiting growth. On Western blot analysis of extracts from stomach carcinoma cells, SC‐1 detects a protein of 50 kilodalton (kD) and Fas proteins of approximately 30, 45, and 60 kD. CONCLUSIONS These data indicate that gastric carcinoma cells of the intestinal and diffuse type differ in their expression of the apoptotic receptors SC‐1 and Fas and the tumor suppressor gene product p53. These new data on phenotypic differences support the hypothesis that these two types of stomach carcinoma do not only differ in morphology, growth pattern, and risk factors but also in genetic pathways. Cancer 1997; 79:433‐40. © 1997 American Cancer Society. Adenocarcinomas of the stomach can be divided into intestinal and diffuse types. They differ in their morphology and growth behavior and in addition, as shown in this study, in their expression of the apoptosis‐related cell‐surface receptors SC‐1 and Fas and the tumor suppressor gene product p53.</abstract><cop>New York</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>9028351</pmid><doi>10.1002/(SICI)1097-0142(19970201)79:3&lt;433::AID-CNCR2&gt;3.0.CO;2-J</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 1997-02, Vol.79 (3), p.433-440
issn 0008-543X
1097-0142
language eng
recordid cdi_proquest_miscellaneous_78819760
source Wiley-Blackwell Read & Publish Collection; Elektronische Zeitschriftenbibliothek
subjects Adenocarcinoma - chemistry
Adenocarcinoma - immunology
Adenocarcinoma - physiopathology
Adult
Aged
apoptosis
Apoptosis - physiology
Biological and medical sciences
Blotting, Western
Coloring Agents
diffuse type stomach carcinoma
Electrophoresis
fas Receptor - analysis
Fas/APO‐1/CD95
Female
Frozen Sections
Gastroenterology. Liver. Pancreas. Abdomen
Gene Expression Regulation, Neoplastic
Humans
Immunoenzyme Techniques
intestinal type stomach carcinoma
Male
Medical sciences
Middle Aged
p53
Receptors, Cell Surface - analysis
SC‐1
Stomach
Stomach Neoplasms - chemistry
Stomach Neoplasms - immunology
Stomach Neoplasms - physiopathology
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Tetrazolium Salts
Thiazoles
Tumor Suppressor Protein p53 - analysis
Tumors
title Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T21%3A52%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20expression%20of%20apoptosis%20receptors%20on%20diffuse%20and%20intestinal%20type%20stomach%20carcinoma&rft.jtitle=Cancer&rft.au=Vollmers,%20H.%20Peter&rft.date=1997-02-01&rft.volume=79&rft.issue=3&rft.spage=433&rft.epage=440&rft.pages=433-440&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/(SICI)1097-0142(19970201)79:3%3C433::AID-CNCR2%3E3.0.CO;2-J&rft_dat=%3Cproquest_cross%3E78819760%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4752-3425639efd469e8dc59277262cc498ac8f4aa8bde348b7c0b2ee1a28fcffeab23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=78819760&rft_id=info:pmid/9028351&rfr_iscdi=true